| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Departments of Pathology,
2 Surgery, and
3 Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland;
4 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas;
5 Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and
6 Roswell Park Cancer Institute, Buffalo, New York
Purpose: Pancreatic endocrine neoplasms (PENs) are rare, mostly well-differentiated endocrine neoplasms, whose biology has been poorly characterized. Global expression microarrays can document abnormal pathways that impact on tumorigenesis and disease progression.
Experimental Design: RNA was extracted from eight well-differentiated PENs and three highly enriched pancreatic islet cell samples (80–90% purity), and examined using the Affymetrix U133A oligonucleotide microarray. Microarray data were normalized using dCHIP (www.dCHIP.org) for identification of differentially expressed genes. PEN tissue microarrays were constructed from 53 archival PENs for immunohistochemical validation of microarray data.
Results: Sixty-six transcripts were overexpressed 
3-fold in PENs compared with normal islet cells, including putative oncogenes (MLLT10/AF10), growth factors [insulin-like growth factor-binding protein 3 (IGFBP3)], cell adhesion and migration molecules (fibronectin), and endothelial elements (MUC18/MelCAM and CD31). A total of 119 transcripts were underexpressed 
3-fold in PENs compared with normal islet cells, including cell cycle checkpoint proteins (p21/Cip1), the MIC2 (CD99) cell surface glycoprotein, putative metastasis suppressor genes (NME3), and junD, a MEN1-regulated transcription factor. Using PEN tissue microarrays, we confirmed the differential up-regulation of IGFBP3 (70%) and fibronectin (22%) and differential down-regulation of p21 (46%) and MIC2 (CD99; 91%) in PENs versus normal pancreatic islets. IGFBP3 overexpression was significantly more common in metastatic (93%) versus primary PEN lesions (60%), P = 0.022. Fibronectin overexpression demonstrated a trend toward significance in lymphatic PEN metastases (55%) compared with primary PEN lesions (24%; P = 0.14).
Conclusions: Global expression analysis provides insight into tumorigenic pathways in PENs and may identify potential prognostic and therapeutic markers for these uncommon neoplasms.
This article has been cited by other articles:
|
|
 |
|
  T. R Halfdanarson, J. Rubin, M. B Farnell, C. S Grant, and G. M Petersen Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors Endocr. Relat. Cancer, June 1, 2008; 15(2): 409 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.-M. Duerr, Y. Mizukami, A. Ng, R. J Xavier, H. Kikuchi, V. Deshpande, A. L Warshaw, J. Glickman, M. H Kulke, and D. C Chung Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis Endocr. Relat. Cancer, March 1, 2008; 15(1): 243 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Di Florio, G. Capurso, M. Milione, F. Panzuto, R. Geremia, G. D. Fave, and C. Sette Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells Endocr. Relat. Cancer, March 1, 2007; 14(1): 111 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Fontaniere, J Tost, A Wierinckx, J Lachuer, J Lu, N Hussein, F Busato, I Gut, Z-Q Wang, and C-X Zhang Gene expression profiling in insulinomas of Men1 {beta}-cell mutant mice reveals early genetic and epigenetic events involved in pancreatic {beta}-cell tumorigenesis Endocr. Relat. Cancer, December 1, 2006; 13(4): 1223 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Byun, I.-K. Hong, E. Kim, Y.-J. Jin, D.-I. Jeoung, J.-H. Hahn, Y.-M. Kim, S. H. Park, and H. Lee A Splice Variant of CD99 Increases Motility and MMP-9 Expression of Human Breast Cancer Cells through the AKT-, ERK-, and JNK-dependent AP-1 Activation Signaling Pathways J. Biol. Chem., November 17, 2006; 281(46): 34833 - 34847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cozar-Castellano, N. Fiaschi-Taesch, T. A. Bigatel, K. K. Takane, A. Garcia-Ocana, R. Vasavada, and A. F. Stewart Molecular Control of Cell Cycle Progression in the Pancreatic {beta}-Cell Endocr. Rev., June 1, 2006; 27(4): 356 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Manara, G. Bernard, P.-L. Lollini, P. Nanni, M. Zuntini, L. Landuzzi, S. Benini, G. Lattanzi, M. Sciandra, M. Serra, et al. CD99 Acts as an Oncosuppressor in Osteosarcoma Mol. Biol. Cell, April 1, 2006; 17(4): 1910 - 1921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Cozar-Castellano, M. Weinstock, M. Haught, S. Velazquez-Garcia, D. Sipula, and A. F. Stewart Evaluation of {beta}-Cell Replication in Mice Transgenic for Hepatocyte Growth Factor and Placental Lactogen: Comprehensive Characterization of the G1/S Regulatory Proteins Reveals Unique Involvement of p21cip Diabetes, January 1, 2006; 55(1): 70 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gronborg, T. Z. Kristiansen, A. Iwahori, R. Chang, R. Reddy, N. Sato, H. Molina, O. N. Jensen, R. H. Hruban, M. G. Goggins, et al. Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach Mol. Cell. Proteomics, January 1, 2006; 5(1): 157 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Buchholz, H. A. Kestler, A. Bauer, W. Bock, B. Rau, G. Leder, W. Kratzer, M. Bommer, A. Scarpa, M. K. Schilling, et al. Specialized DNA Arrays for the Differentiation of Pancreatic Tumors Clin. Cancer Res., November 15, 2005; 11(22): 8048 - 8054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maffei, Z. Liu, P. Witkowski, F. Moschella, G. D. Pozzo, E. Liu, K. Herold, R. J. Winchester, M. A. Hardy, and P. E. Harris Identification of Tissue-Restricted Transcripts in Human Islets Endocrinology, October 1, 2004; 145(10): 4513 - 4521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Hansel, A. Rahman, M. House, R. Ashfaq, K. Berg, C. J. Yeo, and A. Maitra Met Proto-Oncogene and Insulin-Like Growth Factor Binding Protein 3 Overexpression Correlates with Metastatic Ability in Well-Differentiated Pancreatic Endocrine Neoplasms Clin. Cancer Res., September 15, 2004; 10(18): 6152 - 6158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kunapuli, C. S. Kasyapa, L. Hawthorn, and J. K. Cowell LGI1, a Putative Tumor Metastasis Suppressor Gene, Controls in Vitro Invasiveness and Expression of Matrix Metalloproteinases in Glioma Cells through the ERK1/2 Pathway J. Biol. Chem., May 28, 2004; 279(22): 23151 - 23157. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
